Benign Prostatic Hyperplasia, or BPH, affects over 40 million men in the United States.1 The condition can cause bothersome urinary symptoms that can worsen with age. Most noticeably, men may have a frequent need to urinate, weak or slow urinary stream, incomplete bladder emptying, difficulty or delay in starting urination, urgent feeling of needing to urinate, and a urinary stream that stops and starts.
Traditional treatments include the use of alpha blockers which can cause unpleasant side effects including dizziness, headaches or sexual dysfunction. And some men may not get adequate relief of their symptoms with this class of medications.2
Surgical options include transurethral resection of the prostate (TURP) or photovaporization of the prostate (PVP). However, these options typically require general anesthesia, overnight hospitalization, and post-operative catheterization. Surgery can also increase the risk of erectile dysfunction or loss of ejaculation.2
TPMG Urologists Dr. Kostiner, Dr. Habibi and Dr. Darby, are excited to offer our patients the Prostatic Urethral Lift procedure using the UroLift® System. The FDA-cleared UroLift System is a minimally invasive procedure to treat the symptoms of BPH that does not require any cutting, heating, or removal of prostate tissue.
Here’s how it works: our Board-certified urologists use the UroLift System device to lift and move the enlarged prostate tissue out of the way so it no longer blocks the urethra. Tiny implants are placed to hold the tissue in place, like tiebacks on a window curtain, leaving an unobstructed pathway for urine to flow again.
Robust clinical data continues to support the UroLift System as the new standard of care for men with BPH. An ongoing multi-center, multi-national real-world study of more than 800 UroLift patients found that the UroLift System offers significant improvement in symptoms and quality of life through 24 months.3
Highlights of the study include3:
With a 40% reduction in IPSS score at 24 months, results were consistent with the data from the randomized, five-year L.I.F.T. study. L.I.F.T. demonstrated that the UroLift System treatment provides a highly tolerable minimally invasive procedural experience, rapid reduction of symptoms after the procedure, and sustained improvements in QoL (Quality of Life) score, IPSS (International Prostate Symptom Score), and Qmax (peak urinary flow rate), while preserving sexual function.
The registry retreatment rate was consistent with L.I.F.T., which demonstrated a retreatment rate of just 2-3% per year, comparing well to the 1-2% expected rate for the gold standard TURP.
Additionally, the registry included patients in urinary retention prior to treatment. Of those with follow up data, 96% were able to urinate without use of a catheter within the first month.
The registry will continue to enroll additional sites and is expected to increase to more than 2,000 patients.
Recently, the FDA cleared new indications for the UroLift System, making patients who have an obstructive median lobe and those as young as 45 now eligible to receive treatment with the UroLift System for their BPH symptoms.
If you have patients who are interested in learning more about this treatment option, visit MyTPMG.com
References
1Berry, et al., J Urol 1984 and 2013 U.S. Census worldwide population estimates
2AUA Guidelines 2003
3Keyes, EAU 2018, Copenhagen
MAC00827-01 Rev A
